News

circle_logo2

CalciMedica Names Life Science Veteran to Its Board of Directors

LA JOLLA, CA, March 26, 2019 /PRNewswire/ — CalciMedica, a clinical-stage biopharmaceutical company developing CM4620, a novel small molecule compound for acute pancreatitis, announced that …

CalciMedica, Inc. to Present Study Population Profile from Its Initial Patient Study of Its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference

LA JOLLA, CA, March 19, 2019 /PRNewswire/ — Physicians from several study sites involved in CalciMedica’s initial acute pancreatitis clinical study of its CRAC channel …

CalciMedica Names Two Senior Executives to Its Board of Directors

LA JOLLA, CA, May 1, 2018 /PRNewswire/ — CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently …

Research Collaboration Between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference

LA JOLLA, CA, January 24, 2018 /PRNewswire/ — Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a …

CalciMedica Receives Fast-Track Designation for CM4620, A Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis

PATIENT STUDIES EXPECTED TO BEGIN IN EARLY 2018 LA JOLLA, Calif., May 24, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced today that it received Fast-track …

Scroll to Top